Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.97 |
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248815 | 0.85 | MEN1 (0.81) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6250292 | 0.85 | MEN1 (0.74) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6246144 | 0.84 | MEN1 (0.83) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL11369250 | 0.84 | ALDH1A1 (0.97) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3277999 | 0.84 | L3MBTL1 (0.95) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL11859393 | 0.84 | MEN1 (0.72) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6246194 | 0.82 | MEN1 (0.76) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL11924459 | 0.82 | MEN1 (0.70) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3278398 | 0.82 | ALDH1A1 (1.00) | GAAMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL5803825 | 0.82 | MEN1 (0.69) | GAAMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | claimed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | claimed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | claimed |
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | disclosed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-7012100-B1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005044008-A2 | 2 -AMINOTHIOPHENE COMPOUNDS AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | disclosed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | disclosed |
| US-4013681-A | SUGAR CANE RIPENERS | HAWAIIAN SUGAR PLANTERS' ASSOCIATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989505-A | Use of polycyclic thiophene compounds as ripeners for sugarcane | HAWAIIAN SUGAR PLANTERS' ASSOCIATION (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, MASTL, BPGM | GAA 365/4885MEN1 2985/4885KMT2A 3792/4885 |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | GAA 1737/4885MEN1 1184/4885KMT2A 4115/4885 |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, PKN1, PKMYT1 | GAA 389/4885MEN1 2405/4885KMT2A 3324/4885 |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | STK4, SBK3, STK17B | GAA 1861/4885MEN1 4022/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.